记忆支持系统可行性研究
记忆支持系统的实施:可行性研究
The purpose of this study is to determining the feasibility of providing the Memory Support System (MSS) to individuals with mild cognitive impairment (MCI) and their partners at a clinic in Ontario, Canada. This will involve a) collecting information from patients referred to the a memory clinic and geriatric day hospital about the patient's interest in and the patient's preferred method to administer the MSS; and b) a cost analysis related to implementation of the MSS. The study will also measure efficacy outcomes of the MSS regarding program adherence as well as to self-reported IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden among a sample of individuals with MCI and their care partners
研究概览
详细说明
A survey will be created and sent out to participants with MCI who have expressed interest in participating in research and have been seen at a memory clinic or geriatric day hospital after the initiation of the study. The survey will consist of a Likert scale and open questions related to patient interest in and preferred length of MSS administration and preference for in-person versus virtual administration.
During and after collection of the survey data, a sample of 20 individuals with MCI (ages ≥50) and their care partners will undergo MSS training.
At enrollment in the MSS training, participants with MCI and their care partners will complete measures of cognitive and functional status. Participants and partners will also complete measures of treatment adherence, IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden at baseline, treatment end, and 8-week follow-up. Participants will complete the MSS training consisting of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after initial assessment. Training will be offered in English or French. After the intervention, participants and their partners will complete a semi-structured interview, seeking suggestions for improving the MSS, teaching curriculum, and intervention logistics.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Neil Thomas, MD
- 电话号码:613-562-6322
- 邮箱:nthomas@bruyere.org
研究联系人备份
- 姓名:Nayna Kirubakar
- 电话号码:1266 613-562-6262
- 邮箱:nkirubakar@bruyere.org
学习地点
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 5C8
- 招聘中
- Bruyère Health Research Institute
-
接触:
- Neil Thomas, MD
- 电话号码:613-562-6322
- 邮箱:nthomas@bruyere.org
-
接触:
- Nayna Kirubakar
- 电话号码:1266 613-562-6262
- 邮箱:nkirubakar@bruyere.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- diagnosis of single or multi-domain MCI
- Clinical Dementia Rating global (CDR) score of ≤ 0.5
- Montreal Cognitive Assessment score of ≥18
- available contact with a care partner ≥ 2 times weekly
- absence or stable intake of nootropic(s) for ≥ 3 months
Exclusion Criteria:
- visual/hearing impairment and/or history of reading or written inability/disability sufficient to interfere with MSS training
- concurrent participation in another related clinical trial
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:记忆支持系统参与者
|
The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Interest in completion of MSS training
大体时间:From study start date up to 19 months.
|
Percentage of participants that complete the feasibility survey and agree or strongly agree with the statement that they are interested in completing MSS training. |
From study start date up to 19 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adherence to French Memory Support System Intervention
大体时间:One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from adherence scores from one week after starting treatment (MSS intervention) at treatment end and at 8 weeks after the treatment end. Using an adherence scale from 0 to 10, with 10 being highest and a cut-off score of ≥ 7 points suggesting adherence with the MSS. |
One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Center for Epidemiologic Studies Depression Scale
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Depression screening scale using Likert scale. Total score of 0-60 points, with higher scores signifying a worse outcome (higher levels of depression). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Everyday Cognition questionnaire.
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report measure of performance based instrumental activities of daily living. Total score of 23-92, with higher scores indicating a worse outcome. |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Functional Assessment Questionnaire
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based report of performance of instrumental activities of daily living. Total score of 0-30, with higher scores indicating a worse outcome (higher level of dependence). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Quality of Life in Alzheimer Disease
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report quality of life scale. Total score of 13-52, with higher scores indicating a better outcome (better quality of life). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report anxiety scale. Total score of 10-40 with higher scores indicating a worse outcome (higher level of anxiety). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Chronic Disease Self-efficacy Scale
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Selected questions related to memory and cognition from self report scale. Total score of 9-90 with higher scores indicating a better outcomes (higher feeling of self-efficacy). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Caregiver Burden Inventory Short-Form
大体时间:Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based scale of level of caregiver burden. Total score of 0-48 with higher scores indicating a worse outcome (higher level of burden). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
合作者和调查者
调查人员
- 首席研究员:Neil Thomas, MD、Bruyère Health Research Institute.
- 首席研究员:Octavio Santos, PhD、Ottawa Hospital Research Institute, Bruyère Health Research Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified data from the study may be shared with other researchers within the HABIT consortium. Data that may be shared will include the results of the feasibility survey and the scores from the baseline, treatment end and 8 week follow up outcome measures collected from participants who complete MSS training.
IPD 共享时间框架
Data will be available after the end date of the study and kept indefinitely.
IPD 共享访问标准
Upon request that is approved by the study principal investigators.
IPD 共享支持信息类型
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.